Increased Interleukin-9 and CD4+IL-9+ T cells in patients with Systemic lupus erythematosus

Molecular Medicine Reports

Volumn 7, Issue 3, 2013, Pages 1031-1037

  Ouyang, Han ^a   Shi, Yongbing ^a   Liu, Zhichun ^a   Feng, Sheng ^a   Li, Lingyun ^a   Su, Nan ^a   Lu, Ying ^a   Kong, Shumin ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Glucocorticoid; Interleukin 9; Systemic lupus erythematosus; Th17 cells

Indexed keywords

ANTINUCLEAR ANTIBODY; CD4 ANTIGEN; COMPLEMENT COMPONENT C3; INTERLEUKIN 9; MESSENGER RNA; METHYLPREDNISOLONE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; LYMPHOID CELL; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT DURATION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-9; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METHYLPREDNISOLONE; MIDDLE AGED; RNA, MESSENGER;

EID: 84873206749     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1258     Document Type: Article

References (24)

1. Rahman A and Isenberg DA: Systemic lupus erythematosus. N Engl J Med 358:929-939, 2008. (Pubitemid 351397092)
2. Herrmann M, Voll RE and Kalden JR: Etiopathogenesis of systemic lupus erythematosus. Immunol Today 9:424-426, 2000.
3. Pan HF, Ye DQ and Li XP: Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat Clin Pract Rheumatol 4:352-353, 2008. (Pubitemid 351974005)
4. Knoops L and Renauld JC: IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors 22:207-215, 2004. (Pubitemid 40123399)
5. Liu Y, Teige I, Birnir B, et al: Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat Med 12:518-525, 2006.
6. Sugimoto T, Ishikawa Y, Yoshimoto T, et al: Interleukin 18 acts on memory T helper cells type 1 to induce airway infl ammation and hyperresponsiveness in a naive host mouse. J Exp Med 199:535-545, 2004. (Pubitemid 38233837)
7. + natural regulatory T cells. Proc Natl Acad Sci USA 106:885-890, 2009.
8. Jager A, Dardalhon V, Sobel RA, et al: Th1, Th17 and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 183:7169-7177, 2009.
9. Soroosh P and Doherty TA: Th9 and allergic disease. Immunology 127:450-458, 2009.
10. Nowak EC and Noelle RJ: Interleukin-9 as a T helper type 17 cytokine. Immunology 131:169-173, 2010.
11. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classifi cation of systemic lupuserythematosus. Arthritis Rheum 25:1271-1277, 1982. (Pubitemid 13221242)
12. Bombardier C, Gladman DD, Urowitz MB, et al: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630-640, 1992.
13. Nowak EC, Weaver CT, Turner H, et al: IL-9 as a mediator of Th17-driven infl ammatory disease. J Exp Med 206:1653-1660, 2009.
14. Poulin LF, Richard M, Le Moine A, et al: Interleukin-9 promotes eosinophilic rejection of mouse heart allografts. Transplantation 76:572-577, 2003. (Pubitemid 37013265)
15. Tsuji F, Yoshimi M, Katsuta O, et al: Point mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen. induced arthritis in DBA/1J mice. BMC Musculoskelet Disord 10:23, 2009.
16. Khan IH, Krishnan VV, Ziman M, et al: A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. Cytometry B Clin Cytom 76:159-168, 2009.
17. Brink I, Thiele B, Burmester GR, et al: Effects of anti-CD4 antibodies on the release of IL-6 and TNF-alpha in whole blood samples from patients with systemic lupus erythematosus. Lupus 8:723-730, 1999.
18. + natural regulatory T cells. Proc Natl Acad Sci USA 106:12885-12890, 2009.
19. Tzartos JS, Manuel AF, Matthew JC, et al: Interleukin-17 production in central nervous system-infi ltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172:146-155, 2008. (Pubitemid 351186376)
20. Beriou G, Bradshaw EM, Lozano E, et al: TGF-b induces IL-9 production from human Th17 cells. J Immunol 185:46-54, 2010.
21. Koichi Y, Ayumi Y, Yoshihide A, et al: Serum interleukin 9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis. J Rheumatol 38:2193-2197, 2011.
22. Lu LF, Lind EF, Gondek DC, et al: Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442:997-1002, 2006. (Pubitemid 44330250)
23. Yang L, Aozasa K, Oshimi K, et al: Epstein-Barr virus (EBV) encoded RNA promotes growth of EBV-infected T cells through interleukin-9 induction. Cancer Res 64:5332-5337, 2004. (Pubitemid 39006553)
24. + anaplastic large-cell lymphoma cells. Blood 108:2407-2415, 2006. (Pubitemid 44497526)